SCHEMBL15057785

SCHEMBL15057785

NC1(C(=O)O)CC(Cl)C1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15060220 0.78
SCHEMBL659587 0.76 GRM4 (1.00)
SCHEMBL13319984 0.76 GRM4 (1.00)
SCHEMBL9058677 0.76 GRM4 (0.58)
SCHEMBL25492080 0.76 GRM4 (0.58)
SCHEMBL23833793 0.76 GRM4 (0.58)
SCHEMBL25492075 0.76 GRM4 (0.58)
SCHEMBL25492047 0.76 GRM4 (0.58)
Fluciclovine SCHEMBL5934962 0.76
Fluciclovine F18 SCHEMBL1449765 0.76

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220111052-A1 ELUENT SOLUTION GE HEALTHCARE LTD (GB) 2022-04-14 US claimed
EP-3766522-B1 AUTOMATED METHOD FOR THE PREPARATION OF 18F-FLUCICLOVINE COMPOSITIONS GE HEALTHCARE LTD (GB) 2022-03-23 EP claimed
EP-3766522-A1 AUTOMATED METHOD FOR THE PREPARATION OF 18F-FLUCICLOVINE COMPOSITIONS GE Healthcare Limited (GB) 2021-01-20 EP claimed
EP-2793954-B1 18F-FLUCICLOVINE COMPOSITIONS IN CITRATE BUFFERS GE HEALTHCARE LTD (GB) 2020-10-21 EP claimed
US-20150231249-A1 18F-FLUCICLOVINE COMPOSITIONS IN CITRATE BUFFERS GE HEALTHCARE LIMITED (GB) 2015-08-20 US claimed
EP-2793954-A1 18F - FLUCICLOVINE COMPOSITIONS IN CITRATE BUFFERS GE Healthcare UK Limited (GB) 2014-10-29 EP claimed
WO-2013093025-A1 18F - FLUCICLOVINE COMPOSITIONS IN CITRATE BUFFERS GE HEALTHCARE LIMITED (GB) 2013-06-27 WO claimed
US-11534494-B2 Formulation and method of synthesis GE HEALTHCARE LIMITED (GB) 2022-12-27 US disclosed
US-20220111052-A1 ELUENT SOLUTION GE HEALTHCARE LTD (GB) 2022-04-14 US disclosed
EP-3766522-B1 AUTOMATED METHOD FOR THE PREPARATION OF 18F-FLUCICLOVINE COMPOSITIONS GE HEALTHCARE LTD (GB) 2022-03-23 EP disclosed
US-20220001034-A1 NOVEL FORMULATION AND METHOD OF SYNTHESIS GE HEALTHCARE LTD (GB) 2022-01-06 US disclosed
US-11077216-B2 Formulation and method of synthesis GE HEALTHCARE LIMITED (GB) 2021-08-03 US disclosed
EP-3431460-B1 NOVEL FORMULATION AND METHOD OF SYNTHESIS GE HEALTHCARE LTD (GB) 2021-02-17 EP disclosed
EP-3160923-B1 NOVEL FORMULATION AND METHOD OF SYNTHESIS GE HEALTHCARE LTD (GB) 2019-01-02 EP disclosed
US-20170128597-A1 NOVEL FORMULATION AND METHOD OF SYNTHESIS GE HEALTHCARE LIMITED (GB) 2017-05-11 US disclosed
EP-3160923-A1 NOVEL FORMULATION AND METHOD OF SYNTHESIS GE Healthcare Limited (GB) 2017-05-03 EP disclosed
WO-2016001199-A1 NOVEL FORMULATION AND METHOD OF SYNTHESIS GE HEALTHCARE LIMITED (GB) 2016-01-07 WO disclosed
US-20150231249-A1 18F-FLUCICLOVINE COMPOSITIONS IN CITRATE BUFFERS GE HEALTHCARE LIMITED (GB) 2015-08-20 US disclosed
EP-2793954-A1 18F - FLUCICLOVINE COMPOSITIONS IN CITRATE BUFFERS GE Healthcare UK Limited (GB) 2014-10-29 EP disclosed
WO-2013093025-A1 18F - FLUCICLOVINE COMPOSITIONS IN CITRATE BUFFERS GE HEALTHCARE LIMITED (GB) 2013-06-27 WO disclosed